Skip to Content

Elevance Health Inc

ELV: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$596.00CtpxzhtShhftccwl

Elevance Earnings: Mix Shift Boosts Bottom Line and 2024 Outlook Slightly

Narrow-moat Elevance delivered slightly higher first-quarter results than expected and mildly increased its 2024 guidance, despite continued medical membership losses from Medicaid eligibility redeterminations. Our near- and long-term forecasts have not changed materially, and we do not anticipate changing our $520 fair value estimate. Recent trades appear close to fair value.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ELV so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center